Development of low density azithromycin-loaded polycaprolactone microparticles for pulmonary delivery

References

• Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral pneumonia. Lancet 2011;377:1264–75
   PubMed Web of Science ®Google Scholar
• Togami K, Chono S, Morimoto K. Distribution characteristics of clarithromycin and azithromycin, macrolide antimicrobial agents used for treatment of respiratory infections, in lung epithelial lining fluid and alveolar macrophages. Biopharm Drug Dispos 2011;32:389–97
   PubMed Web of Science ®Google Scholar
• Lode H, Borner K, Koeppe P, Schaberg T. Azithromycin – review of key chemical, pharmacokinetic and microbiological features. J Antimicrob Chemother 1996;37C:1–8
   Google Scholar
• Wang H, Chen M, Xua Y, et al. Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the Community-Acquired Respiratory Tract Infection Pathogen Surveillance (CARTIPS) study, 2009–2010. Int J Antimicrob Agents 2011;38:376–83
   PubMed Web of Science ®Google Scholar
• Hickey AJ, Lu D, Ashley ED, Stout J. Inhaled azithromycin therapy. J Aerosol Med 2006;19:54–60
   PubMedGoogle Scholar
• Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. J Clin Pharmacol 2003;56:588–99
   Web of Science ®Google Scholar
• Learoyd TP, Burrows JL, French E, Seville PC. Chitosan-based spray-dried respirable powders for sustained delivery of terbutaline sulfate. Eur J Pharm Biopharm 2008;68:224–34
   PubMed Web of Science ®Google Scholar
• Kim I, Byeon HJ, Kim TH, et al. Doxorubicin-loaded highly porous large PLGA microparticles as a sustained release inhalation system for the treatment of metastatic lung cancer. Biomaterials 2012;33:5574–83
   PubMed Web of Science ®Google Scholar
• Mezzena M, Scalia S, Young PM, Traini D. Solid lipid budesonide microparticles for controlled release inhalation therapy. AAPS J 2009;11:771–8
   PubMed Web of Science ®Google Scholar
• Gupta V, Rawat A, Ahsan F. Feasibility study of aerosolized prostaglandin E1 microspheres as a noninvasive therapy for pulmonary arterial hypertension. J Pharm Sci 2010;99:1774–89
   PubMed Web of Science ®Google Scholar
• Geiser M, Casaulta M, Kupferschmid B, et al. The role of macrophages in the clearance of inhaled ultrafine titanium dioxide particles. Am J Respir Cell Mol Biol 2008;38:371–6
   PubMed Web of Science ®Google Scholar
• Edwards DA, Hanes J, Caponetti G, et al. Large porous particles for pulmonary drug delivery. Science 1997;276:1868–71
   PubMed Web of Science ®Google Scholar
• Edwards DA, Ben-Jebria A, Langer R. Recent advances in pulmonary drug delivery using large, porous inhaled particles. J Appl Physiol 1998;85:379–85
   PubMed Web of Science ®Google Scholar
• Yang Y, Bajaj N, Xu P, et al. Development of highly porous large PLGA microparticles for pulmonary drug delivery. Biomaterials 2009;30:1947–53
   PubMed Web of Science ®Google Scholar
• Kim I, Byeon HJ, Kim TH, et al. Doxorubicin-loaded highly porous large PLGA microparticles as a sustained release inhalation system for the treatment of metastatic lung cancer. Biomaterials 2013;33:5574–83
   Web of Science ®Google Scholar
• Kawakami K, Hasegawa Y, Zhang S, et al. Low-density microparticles with petaloid surface structure for pulmonary drug delivery. J Pharm Sci 2014;103:1309–13
   PubMed Web of Science ®Google Scholar
• Woodruff MA, Hutmacher DW. The return of a forgotten polymer – polycaprolactone in the 21st century. Prog Polym Sci 2010;35:1217–56
   Web of Science ®Google Scholar
• European Pharmacopoeia. 4th edn., v. 1.0. 4th edn. Strasbourg: Convention on the Elaboration of a European Pharmacopoeia; 2002
   Google Scholar
• Arnold MM, Gorman EM, Schieber LJ, et al. NanoCipro encapsulation in monodisperse large porous PLGA microparticles. J Control Release 2007;121:100–9
   PubMed Web of Science ®Google Scholar
• Silva LFC, Kasten G, Campos CEM, et al. Preparation and characterization of quercetin-loaded solid lipid microparticles for pulmonary delivery. Powder Technol 2013;239:183–92
   Web of Science ®Google Scholar
• Ghari T, Kobarfard F, Mortazavi SA. Development of a simple RP-HPLC-UV method for determination of azithromycin in bulk and pharmaceutical dosage forms as an alternative to the USP method. Iran J Pharm Res 2013;12:57–63
   PubMed Web of Science ®Google Scholar
• Costa P, Lobo JMS. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 2001;13:123–33
   PubMed Web of Science ®Google Scholar
• Izumikawa S, Yoshioka S, Aso Y, Takeda Y. Preparation of poly(l-lactide) microspheres of different crystalline morphology and effect of crystalline morphology on drug release rate. J Control Release 1991;15:133–40
   Web of Science ®Google Scholar
• Nihant N, Schugens C, Grandfils C, et al. Polylactide microparticles prepared by double emulsion/evaporation technique. I. Effect of primary emulsion stability. Pharm Res 1994;11:1479–84
   Google Scholar
• Bosquillon C, Lombry C, Préat V, Vanbever R. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. J Control Release 2007;70:329–39
   Web of Science ®Google Scholar
• Oh YJ, Lee J, Seo JY, et al. Preparation of budesonide-loaded porous PLGA microparticles and their therapeutic efficacy in a murine asthma model. J Control Release 2011;150:56–62
   PubMed Web of Science ®Google Scholar
• Vanbever R, Mintzes JD, Wang J, et al. Formulation and physical characterization of large porous particles for inhalation. Pharm Res 1999;16:1735–42
   PubMed Web of Science ®Google Scholar
• Li Q, Rudolph V, Weigl B, Earl E. Interparticle van der Waals force in powder flowability and compactibility. Int J Pharm 2004;280:77–93
   PubMed Web of Science ®Google Scholar
• Valot P, Baba M, Nedelec J-M, Sintes-Zydowicz N. Effects of process parameters on the properties of biocompatible Ibuprofen-loaded microcapsules. Int J Pharm 2009;369:53–63
   PubMed Web of Science ®Google Scholar
• Balmayor ER, Tuzlakoglu K, Azevedo HS, Reis RL. Preparation and characterization of starch-poly-e-caprolactone microparticles incorporating bioactive agents for drug delivery and tissue engineering applications. Acta Biomater 2008;5:1035–45
   PubMed Web of Science ®Google Scholar
• Ungaro F, Bianca REV, Giovino C, et al. Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs. J Control Release 2009;135:25–34
   PubMed Web of Science ®Google Scholar
• Wang C. A brief history of respiratory deposition modeling. In: Ensor DS, ed. Aerosol science and technology: history and reviews. North Carolina: RTI International; 2011:391–409
   Google Scholar
• Asgharian B, Hofmann W, Bergmann R. Particle deposition in a multiple-path model of the human lung. Aerosol Sci Tech 2001;34:332–9
   Web of Science ®Google Scholar
• Worth Longest P, Holbrook LT. In silico models of aerosol delivery to the respiratory tract–development and applications. Adv Drug Deliv Rev 2015;64:296–311
   Web of Science ®Google Scholar
• Kim YH, Shing KS. Supercritical fluid-micronized ipratropium bromide for pulmonary drug delivery. Powder Technol 2008;182:25–32
   Web of Science ®Google Scholar
• Price OT, Asgharian B, Miller FJ, et al. Multiple Path Particle Dosimetry model (MPPD v1.0): a model for human and rat airway particle dosimetry (Report No. 650010030). [CD-ROM]. Bilthoven, The Netherlands: National Institute of Public Health and the Environment (RIVM); 2002
   Google Scholar
• Montejo-Bernardo J, García-Granda S, Bayod-Jasanada M, et al. An easy and general method for quantifying azithromycin dihydrate in a matrix of amorphous azithromycin. Arkivoc 2005;IX:321–331
   Google Scholar
• Jeong J-C, Lee J, Cho K. Effects of crystalline microstructure on drug release behavior of poly(e-caprolactone) microspheres. J Control Release 2003;92:249–58
   PubMed Web of Science ®Google Scholar
• Natarajan V, Krithica N, Madhan B, Sehgal PK. Formulation and evaluation of quercetin polycaprolactone microspheres for the treatment of rheumatoid arthritis. J Pharm Sci 2011;100:195–205
   PubMed Web of Science ®Google Scholar
• Timoumi S, Mangin D, Peczalski R, et al. Stability and thermophysical properties of azithromycin dehydrate. Arab J Chem 2014;7:189–95
   Web of Science ®Google Scholar
• D’Souza SS, DeLuca PP. Development of a dialysis in vitro release method for biodegradable microspheres. AAPS PharmSciTech 2005;6:E323–8
   PubMed Web of Science ®Google Scholar
• Wang X, Wang Y, Wei K, et al. Drug distribution within poly(e-caprolactone) microspheres and in vitro release. J Mater Process Technol 2009;209:348–54
   Web of Science ®Google Scholar
• Coccoli V, Luciani A, Orsi S, et al. Engineering of poly (e-caprolactone) microcarriers to modulate protein encapsulation capability and release kinetic. J Mater Sci: Mater Med 2008;19:1703–11
   PubMed Web of Science ®Google Scholar
• Pérez MH, Zinutti C, Lamprecht A, et al. The preparation and evaluation of poly(e-caprolactone) microparticles containing both a lipophilic and a hydrophilic drug. J Control Release 2000;65:429–38
   PubMed Web of Science ®Google Scholar